But a new class of weight-loss drugs could change all of that, and represents a big opportunity for investors.
But a new class of GLP-1 weight-loss drugs has the potential to change that, and it represents a big opportunity for investors.
Popular drugs include Ozempic and Wegovy from Novo Nordisk, and Mounjaro from Eli Lilly.
AdvertisementAdvertisementA recent study from Novo Nordisk showed that its Wegovy drug reduced the chance of heart attacks, strokes, and cardiovascular deaths by 20%.
Novo Nordisk became the biggest European company, as measured by market value, earlier this week, so investors are starting to catch on.
Persons:
Goldman Sachs, Jenny Chang, Eli Lilly, Chang, Eli Lilly's
Organizations:
Service, Novo Nordisk
Locations:
Wall, Silicon, Novo